Accelerating Innovations to Address Heavy Menstrual Bleeding in Women in Low-Resource Settings
Funds collaborative early-stage research and tool development for new small molecule antibiotics targeting Klebsiella spp. and other Gram-negative Enterobacteriaceae.
Browse similar grants
Funder: Bill and Melinda Gates Foundation
Due Dates: Letter of Inquiry: May 15, 2025 | Full proposal (by invitation): July 31, 2025 (approximate; subject to invitation)
Funding Amounts: Up to $5,000,000 USD total per project for up to 3 years; exploratory projects with lower budgets/durations encouraged.
Summary: Funds collaborative, early-stage research and tool development for direct-acting small molecule antibiotics targeting Klebsiella spp. and other Enterobacteriaceae.
Key Information: Applicants must join a consortium and comply with data sharing; only one application as lead PI per applicant.
Description
This opportunity supports innovative, multidisciplinary research to accelerate the discovery of direct-acting small molecule antibiotics with broad-spectrum activity against Gram-negative Enterobacteriaceae, focusing initially on Klebsiella spp. Projects may develop new biological, chemical, or AI tools for antibiotic discovery, generate chemical starting points, or improve understanding of compound penetration and resistance. The initiative, a joint effort from the Bill & Melinda Gates Foundation, Novo Nordisk Foundation, and Wellcome, forms a consortium to foster collaboration and collective progress in early drug discovery. All grantees will participate in a consortium-wide data sharing agreement and are expected to work collaboratively toward shared objectives.
